Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US NGO in eye of Indian storm after panel reports HPV vaccine trial irregularities

This article was originally published in SRA

Executive Summary

Another damning report by an Indian parliamentary panel on clinical trials, this time with scathing comments against the US-based non-profit organization PATH over the conduct of studies concerning human papillomavirus (HPV) vaccines, could potentially have serious implications for Merck & Co's Gardasil and GlaxoSmithKline's Cervarix vaccines in the country1.

You may also be interested in...

India Ethical Guidelines For Research: Pertinent – But Less May Be More?

India's draft revised ethical guidelines for biomedical and health research involving human participants covers a raft of new and existing segments. It expands on "specialized" areas such as "informed consent" and "vulnerability" – complex and delicate issues in the Indian context - but some experts say that the multiplicity of "overlapping" rules and guidelines could complicate compliance efforts.

Novartis Says It Hired Over 1,600 Amid Job Cuts Speculation In India

Novartis counters speculation around pandemic-related staff cutbacks in India, saying that it actually upped the number of hires across its operations since January 2020. A senior executive separately provides a buoyant outlook for the Swiss firm’s global services operations in Hyderabad, which has added a significant number of new roles.

Lundbeck Pursues Brintellix Infringement Charges In India

Lundbeck seeks to ward off Alembic and Hetero over alleged patent infringing activity pertaining to its depression therapy vortioxetine in India. The product is seen as one of the key drivers of growth in 2021 for the Danish company, which has settled infringement proceedings with over half a dozen generic opponents so far in the US.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts